Hypertension and accelerated atherosclerosis in endstage renal disease

Journal of Nephrology

Volumn 11, Issue 4, 1998, Pages 185-195

  Huysmans, Kristien ^b   Lins, Robert L ^b   Daelemans, Ronald ^b   Zachée, Pierre ^b   De Broe, Marc E ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b NONE

Author keywords

Atherogenesis; Atherosclerosis; Cardiovascular risk factor; Carotid artery; Chronic renal failure; Epidemiology; Hypertension; Pathogenesis; Ultrasound

Indexed keywords

GLUCOSE; HOMOCYSTEINE; LIPID; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; PARATHYROID HORMONE; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CORONARY RISK; DIALYSIS; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; OXIDATIVE STRESS; UREMIA;

ANIMALS; ARTERIOSCLEROSIS; HUMANS; HYPERTENSION, RENAL; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; RISK FACTORS;

EID: 0031851058     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (117)

1. Ritz E, Koch M. Morbidity and mortality due to hypertension in patients with renal failure. Am J Kidney Dis 1993; 21 (Suppl 2): 113-8.
2. Cohen J, Harrington J, Madias N. Morbidity and mortality in dialysis patients. Kidney Int 1994; 46: 1728-37.
3. Lidner A, Charra B, Sherrard DJ, Scriber BM. Accelerated atherosclerosis in prolonged hemodialysis. New Engl J Med 1974; 290: 697-701.
4. Raine A, Margreiter R, Brunner F, et al. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 1992; Suppl 2: 7-35.
5. Kindler J, Sieberth H, Hahn R, Glokner W, Vlaho M. Does atherosclerosis caused by dialysis limit this treatment? Proc EDTA 1982; (19) 168-74.
6. Ritz E, Deppisch R, Stier E, Hansch G. Atherogenesis and cardiac death: are they related to dialysis procedure and biocompatibility? Nephrol Dial Transplant 1994; (9, Suppl 2): 165-72.
7. Vincenti F, Amend W, Abele J, Feduska N, Salvatierra O. The role of hypertension in hemodialysis-associated atherosclerosis. Am J Med 1980; (68): 363-9.
8. Lameire N. Cardiovascular risk factors and blood pressure control in continuous ambulatory peritoneal dialysis. Perit Dial Int 1992; (13, Suppl 2): 394-423.
9. Ma K, Greene E, Raij L. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kidney Dis 1992; (19): 505-13.
10. Rostand S, Kirk K, Rutsky E. Dialysis-associated ischemic heart disease: insights from coronary angiography. Kidney Int 1984; (25): 653-9.
11. Rostand S, Kirk K, Rutsky E. Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease. Kidney Int 1982; 22: 304-8.
12. Amann K, Wiest G, Zimmer G, Gretz N, Ritz E, Mall G. Reduced capillary density in the myocardium of uremic rats. A sterological study. Kidney Int 1992; 42: 1079-85.
13. Ritz E, Rambausek M, Mall G, Ruffmann K, Mandelbaum A. Cardiac changes in uraemia and their possible relationship to cardiovascular instability on dialysis. Nephrol Dial Transplant 1990; (Suppl 1): 93-7.
14. Huting J, Kramer W, Schutterle G, Wizemann V. Analysis of left ventricular changes associated with chronic hemodialysis. Nephron. 1988; 49: 284-290
15. Messerli F, Ventura H, Elizardi D, Dunn F, Frohlich E. Hypertension and sudden death. Am J Med 1984; 77: 18-22.
16. Silberberg J, Barre P, Prichard S, Sniderman A. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989; 36: 286-90.
17. Mall G, Huther W, Schneider J, Lundin P, Ritz E. Diffuse intermyocardiocytic fibrosis in uremic patients. Nephrol Dial Transpl 1990; 5: 39-44.
18. Lameire N, Bernaert P, Lambert M, Vijt D. Cardiovascular risk factors and their management in patients on continuous ambulatory peritoneal dialysis. Kidney Int 1994; (46): 31-8.
19. Sharrett A. Invasive versus non-invasive studies of risk factors and atheroslerosis. Circulation 1993; (87 Suppl 2): 48-53.
20. Kuller L. Why measure atherosclerosis. Circulation 1993; (87, Suppl 2): 34-7.
21. Schwartz C, Valente A, Hildebrandt E. Prevention of atherosclerosis and end organ damage: a basis for antihypertensive interventional strategies. J Hypertens 1994; (12, Suppl 5): 3-11.
22. Briner V, Luscher T. Role of vascular endothelial abnormalities in clinical medicine. Advan Int Med 1994; 39: 1-22.
23. Reddy K, Nair R, Sheehan H, Hodgson J. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol 1994; 23 (4): 833-13.
24. Alexander R. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension 1995; 25 (2): 155-61.
25. Lyons T. Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol 1993; (71): 26B-31B.
26. Bucala R, Vlassara H. Advanced glycation end products in diabetic renal and vascular disease. Am J Kidney dis 1995; (26): 875-88.
27. Schmidt A, Hori O, Brett J, Yan S, Wautier J. Cellular receptors for advanced glycation end products. Arterioscler Thromb 1994; (14): 1521-8.
28. Vlassara H, Brownlee M, Cerami A. Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors. J Exp Med 1986; 164: 1301-9.
29. Bucala R, Tracey K, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 432-8.
30. Eposito C, Gerlach H, Brett J, Stern D, Vlassara H. Endothelial receptor mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 1989; 170: 1387-407.
31. Steinbrecher U, Witztum J. Glucosylation of low density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 1984; 33: 130-4.
32. Morel D, Hessler J, Chisolm G. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res 1983; 24: 1070-6.
33. Steinberg D, Parthasarathy S, Carew T, Khoo J, Witztum J. Modifications of low-density lipoprotein that increases its atherogenicity. N Engl J Med 1989; 320: 915-24.
34. Vaughn M, Virella G, Lopes-Virella M. Diabetes, autoimmunity and arteriosclerosis. Clin Immunol Immunopathol 1989; 52: 414-20.
35. Wolff S, Dean R. Glucose autoxidation and protein modification. Biochem J 1987; 245: 243-50.
36. Ritz E, Vallance P, Nowicki M. The effect of malnutrition on cardiovascular mortality in dialysis patients: is 1-arginine the answer? Nephrol Dial Transplant 1994; (9): 129-30.
37. Raines E, Ross R. Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J 1993; (69, Suppl): 30-7.
38. Noll G, Luscher T. Influence of lipoproteins on endothelial function. Thromb Res 1994; (74, Suppl 1): 45-54.
39. Vane J, Anggard E, Botting R. Regulatory functions of the vascular endothelium. N Engl J Med 1990; 323: 27-36.
40. Makita Z, Bucala R, Rayfield E, et al. Diabetic-uremic serum advanced glycosylation end-products are chemically reactive and resistant to dialysis therapy: role in mortality of uremia. Lancet 1994; 343: 1519-22.
41. Greten J, Kreis I, Wiesel K, et al. Receptors for advanced glycation end-products (AGE)-expression by endothelial cells in non-diabetic uraemic patients. Nephrol Dial Transplant 1996; 11: 786-90.
42. Schmidt A, Zhang J, Crandall J, et al. Interaction of advanced glycation end-products with their endothelial cell receptor leads to enhanced expression of VCAM-1. FASEB J 1994; 8: Abstract A 662.
43. Attman P, Aloupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia; Relation to renal function and dialysis. Nephron 1991; (57): 401-10.
44. Staprans I, Felts J, Zacherle B. Apoprotein compositions of plasma lipoproteins in uremic patients on hemodialysis. Clin Chim Acta 1979; 93: 135-43.
45. Schaefer F, Ritz E. Metabolic disorders in chronic renal failure. In: Cameron S. et al, eds. Oxford Textbook of Clinical Nephrology. Oxford: Oxford University Press 1992: 1251-64.
46. Becker B, Himmelfarb J, Henrich W, Hakim R. Reassessing the cardiac risk profile in chronic hemodialysis patients. J of the Am Soc of Nephrol 1997; 475-86.
47. Mordasini R, Frey F, Flury W, et al. Selective deficiency of hepatic triglyceride lipase in uremic patients. N Engl J Med 1977; 297: 1362.
48. Pasternack A, Vanttinen T, Solakivi T, Kuusi T, Korte T. Normalisation of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure. Clin Nephrol 1987; 27(4): 163-8.
49. Sowers J, Sowers P, Peuler J. Role of insulin resistance and hyperinsulinemia in development of hypertension and atherosclerosis. J Lab Clin Med 1994; 123 (5): 647-52.
50. Ong - Ajyooth L, Sirisalee K, Shayakul C, Vareesangthip K, Vasuvattakul S. Comparison of lipid abnormalities in continuous ambulatory peritoneal dialysis and hemodialysis patients. Transplant Proc 1994; (26): 2077-9.
51. Olefsky J, Farquhar J, Reaven G. Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med 1974; 57: 551.
52. Kawaguchi Y, Kubo H, Yamamoto H, et al. Is atherosclerosis accelerated in CAPD? Perit Dialysis Intern 1996; 16(Suppl 1): S223-30.
53. Havel R. A biology of cholesterol, lipoproteins and atherosclerosis. Clin and exper hypertens - theory and practice 1989; (A 11): 887-900.
54. Westhuyzen J, Adams C, Fleming S. Evidence for oxidative stress during in vitro dialysis. Nephron 1995; 70: 49-54.
55. Haklar G, Yegenaga I, Yalcin A. Evaluation of oxidant stress in chronic hemodialysis patients: use of different parameters. Clin Chim Acta 1995; 234: 109-14.
56. Maggi E, Bellazzi R, Falaschi F, Frattoni A, Perani G. Enhanced LDL oxidation in uremic patients; an additional mechanism for accelerated atherosclerosis? Kidney Int 1994; (45): 876-83.
57. De Broe M, Heyrman R, De Backer W, Verpooten G, Vermeire P. Pathogenesis of dialysis-induced hypoxemia: a short overview. Kidney Int 1988; (33, Suppl 24): 57-61.
58. Fortin L, Genest J. Measurement of homocysteine in the prediction of arteriosclerosis. Clin Biochem 1995; 28 (2): 155-62.
59. Van den Berg M, Boers G, Franken D, et al. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995; 25: 176-81.
60. Jacob R, Burn B. Oxidative damage and defense. Am J Clin Nutr 1996; 63: 985S-90.
61. Janssen M, Van den Berg M, Stehouwer C, Boers G. Hyperhomocysteinaemia: a role in the accelerated atherogenesis of chronic renal failure? Neth J Med 1995; 46 (5): 244-51.
62. Spitz I, Rubenstein A, Bersohn I, Abrahams C, Lowy C. Carbohydrate metabolism in renal disease. Q J Med 1970; (39 No 154): 201-26.
63. McCaleb M, Wish J, Lockwood D. Insulin resistance in chronic renal failure. Endocrine research 1985; 11 (1-2): 113-25.
64. Akmal M, Massry S, Goldstein D, Fanti P, Weisz A, Defronze A. Role of parathyroid hormone in the glucose intolerance of chronic renal failure. J Clin Invest 1985; 75: 1037-44.
65. Standl E. Hyperinsulinemia and atherosclerosis. Clin Invest Med 1995; 18 (4): 261-6.
66. Massry S, Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin in Nephrol 1994; (14): 219-31.
67. Akmal M, Kasim S, Soliman A, Massry S. Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int 1990; 37: 854-8.
68. Massry S. Is parathyroid hormone a uremic toxin? Nephron 1977; (19): 125-30.
69. Rostand S, Kirk K, Rutsky E. Dialysis-associated ischemic heart disease: insights from coronary angiography. Kidney Int 1984; 25: 653-9.
70. Tomita J, Kimura G, Inoue T, Inenaga T, Sanai T. Role of systolic blood pressure in determining prognosis of hemodialyzed patients. Am J Kidney Dis 1995; (25): 405-12.
71. Drew P, Cunningham J, Evans S, Marsh F, Goodwin F. The effect of cigarette smoking and previous hypertension on the survival of patients treated by continuous ambulatory peritoneal dialysis. Perit Dial Bull 1985; 27-30.
72. Burdick L, Periti M, Salvaggio A, Bertoli S, Mangiarotti R. Relation between carotid artery atherosclerosis and the time on dialysis. A non invasive study in vivo. Clin Nephrol 1994; (42): 121-6.
73. A Hoeks, P Brands, R Reneman. Assessment of the arterial distension waveform using doppler signal processing. J Hypertens 1992; (10, Suppl 6): 19-22.
74. Terenzi T, Gallagher D, De Meersman R, Beadle E, Muller D. The age-related advancement of arterial diasease measured by doppler ultrasound diastolic flow, analysis. J Manipulative Physiol Ther 1993; (16): 527-36.
75. Reed D. Which risk factors are associated with atherosclerosis? Am J Epidemiol. (Suppl 2): 54-5.
76. Blankenhorn D, Hodis H. Arterial imaging and atherosclerosis reversal. Arterioscler Thromb 1994; (14): 177-92.
77. Bots M, Hofman A, Grobbee D. Common carotid intima - media thickness and lower extremity arterial atherosclerosis. Arterioscler Thromb 1994; (14): 1885-91.
78. Young W, Gofman J, Tandy R, Malamud N, Waters E. The quantation of atherosclerosis. The extent of correlation of degrees of atherosclerosis within and between the coronary and cerebral vascular beds. Am J Cardiol 1960; 6: 300-8.
79. Solberg L, Mc Garry P, Moossy J, Strong J, Tejada C, Loken A. Severity of atherosclerosis in cerebral arteries, coronary arteries and aortas. Ann N Y Acad Sci 1968; 149: 956-73.
80. Mitchell J, Schwartz C. Relationship between arterial disease in different sites. Br Med J 1962; 1: 1293-301.
81. Igase P, Kohara K, Kitami Y, Maguchi M, Fukuoka T, Hiwada K. Atherosclerosis of Carotid Artery and End Organ Damages in Essential Hypertensive Patients. J Hypertens 1996; 14 (Suppl 1):S118.
82. Schenk EA, Bond MG, Aretz TH, et al. Multicenter validation study of real time ultrasonography, arteriography and pathology; pathologic evaluation of carotid endarterectomy specimen. Stroke 1988; 19: 289-96.
83. Burdick L, Salvaggio A, Bertoli S, Mangiarotti R, Castagnone D, Anguissola G. Relation between carotid artery atherosclerosis and time on dialysis. A non-invasive study in vivo. Clin Nephrol 1994; 42: 121-6.
84. Duranti E, Imperiali P, Sasdelli M. Is hypertension a mortality risk factor in dialysis? Kidney Int 1996; (S55): S173-4.
85. Degoulet P, Legrain M, Réach I, et al. Mortality risk factors in patients treated by chronic hemodialysis. Nephron 1982; 31: 103-10.
86. Tomita J, Kimura G, Inoue T, et al. Role of systolic blood pressure in determining prognosis of hemodialyzed patients. Am J Kidney Dis 1995; 25 (3): 405-12.
87. Kimura G, Tomita J, Nakamura S, Uzu T, Inenaga T. Interaction between hypertension and other cardiovascular risks in hemodialyzed patients. J Hypertens 1996; 14(Suppl 1): S194.
88. Shaldon S. Unanswered questions pertaining to dialysis adequacy in 1992. Kidney Int 1993; (43, Suppl 41): 274-7.
89. Charra B, Calemard E, Ruffet M, Chazot C, Terrat J. Surviral as an index of adequacy of dialysis. Kidney Int 1992; (41): 1286-91.
90. Charra B, Calemard E, Cuche M, Laurent G. Control of hypertension and prolonged survival on maintenance hemodialysis. Nephron 1983; (33): 96-9.
91. Rossi A, Bonfante L, Giacomini A, et al. Carotid artery lesions in patients with nondiabetic chronic renal failure. Am J Kidney Dis 1996; 27: 58-66.
92. Cheigh JS, Milite C, Sullivan JF, Rubin AL, Stenzel KH. Hypertension is not adequately controlled in hemodialysis patients. Am J Kidney Dis 1992; 19: 453-9.
93. de Leeuw P. Pathophysiology of hypertension in patients on renal replacement therapy. Blood Purif 1994; (12): 245-51.
94. Broer P, Koomans H, Dorhout Mees E. Renin and blood volume in chronic renal failure: A comparison with essential hypertension. Nephron. 1987; 45: 7-15.
95. Wilkinson R, Scott D, Uldall P, Kerr D, Swinney J. Plasma renin and exchangeable sodium in the hypertension of chronic renal failure. Q J Med. 1970; 309: 377-94.
96. Schnitze Georg, Piefke S, Molzahn M. Blood pressure in terminal renal failure. Nephron 1980; 25: 15-24.
97. Sherman R, Daniel A, Cody R. The effect of interdialytic weight gain on pre-dialysis blood pressure. Artif Organs 1993; (17): 770-4.
98. Chazot C, Charra B, Laurent G, Didier C, Vo Van C. Interdialysis blood pressure control by long haemodialysis sessions. Nephrol Dial Transplant 1995; (10): 831-7.
99. Vertes V, Cangiano J, Berman L, Gould A. Hypertension in end-stage renal disease. N Engl J Med. 1969; 280: 978-81.
100. Salem MM. Hypertension in the hemodialysis population: a survey of 649 patients. Am J Kidney Dis 1995; 26/3: 461-8.
101. Sulkova S, Valek A. Role of antihypertensive drugs in the therapy of patients on regular dialysis treatment. Kidney Int 1988; (34): 198-200.
102. Losonczy G, Walter J, Mucha I, Taraba I. Changes of arterial prostaglandin E2 during haemodialysis. Nephrol Dial Transplant 1990; (5): 937-41.
103. Schalekamp M, Beevers G, Briggs J, et al. Hypertension in chronic renal failure. An abnormal relation between sodium and the renin-angiotensin system. Am J Med 1973; 55: 379-90.
104. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-5.
105. Ritz E, Koomans H. New insights into mechanisms of blood pressure regulation in patients with uraemia. Nephrol Dial Transplant 1996; 11(S 2): 52-9.
106. Kwan Eun K, Onesti G, Schwartz A, Chinitz J, Swartz C. Hemodynamics of hypertension in chronic end-stage renal disease. Circulation. 1972; 46: 456-64.
107. Converse R, Jacobsen T, Toto R, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327: 1912-8.
108. Boero R, Guarena C, Berto I, Forneris G, Borca M. Pathogenesis of arterial hypertension in chronic uraemia: the role of reduced Na/K-ATP-ase activity. J Hypertens 1988; (6, Suppl 4): 363-5.
109. Boero R, Guarena C, Berto I, et al. Erythrocyte Na, K pump activity and arterial hypertension in uremic dialyzed patients. Kidney Int 1988; 34: 691-6.
110. Parfitt A. Soft-tissue calcification in uremia. Arch Intern Med 1969; 124: 544-56.
111. Kokot F, Wiecek A. Arterial hypertension in uraemic patients treated with erythropoetin. Nephron 1995; 71: 127-32.
112. Lins R, De Raedt H, Zachee P, Daelemans R. Importance of volume factors in dialysis-related hypertension. New therapeutic strategies in nephrology. Ed Kluwer Academic Publishers: 1990; 268-70.
113. Huisman RM, de Bruin C, Klont D, Smit AJ. Relationship between blood pressure during haemodialysis and ambulatory blood pressure in between dialyses. Nephrol Dial Transplant 1995; 10: 1890-4.
114. Kooman J, Gladziwa U, Bocker G, Wijnen J, v. Bortel L. Blood pressure during the interdialytic period in haemodialysis patients: estimation of representative blood pressure values. Nephrol Dial Transplant 1992; (7): 917-23.
115. Luik AJ, Struijk DG, Gladziwa U, et al. Diurnal blood pressure variations in haemodialysis and CAPD patients. Nephrol Dial Transplant 1994; 9: 1616-21.
116. Rodby RA, Vonesh EF, Korbet SM. Blood pressures in hemodialysis and peritoneal dialysis using ambulatory blood pressure monitoring. Am J Kidn Dis 1994; 23: 401-11.
117. van de Borne P, Tielemans C, Collart F, Vanherweghem JL, Degaute JP. Twenty-four-hour blood pressure and heart rate patterns in chronic hemodialysis patients. Am J Kidn Dis 1993; 22: 419-42.